Patient Driven Research Grants
Learn More
Photo Credit: KCCure
Research
Donate
FDA approves the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of advanced renal cell carcinoma (RCC)
On August 10, 2021, the Food and Drug Administration approved the combination of lenvatinib (Lenvima) plus pembrolizumab (Keytruda) for first-line treatment of ...Read More
No Tie July 2021
What is No Tie July? No Tie July is our annual fundraising effort where we raise $50,000 – one year of research funding – in just one month! Since o...Read More
Patient Driven Research – the KCCure Chromophobe Research Grant
“Has anyone done any fundraising or advocacy projects to help raise money or awareness for Chromophobe RCC? Every specialist I talk to mentions the limited rese...Read More
